2
Announcements
Trials
Browse
Landscape
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Tongue Neoplasms
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Parathyroid Neoplasms
1
Oropharyngeal Neoplasms
1
Neovascularization, Pathologic
1
Nasopharyngeal Neoplasms
1
Mouth Neoplasms
1
Lung Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hyperparathyroidism, Primary
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Parathyroidectomy
5
Cinacalcet
3
fluorocholine
2
belinostat
2
Trastuzumab
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Denosumab
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
lutetium Lu 177 dotatate
1
gallium Ga 68 dotatate
1
fluorodopa F 18
1
evocalcet
1
entinostat
1
acetaminophen, codeine drug combination
1
Tramadol
1
Tablets
1
Standard of Care
1
Specimen Handling
1
Sodium Chloride
1
Rubidium-82
1
Ritonavir
1
Radiotherapy
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Ipilimumab
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parathyroid Neoplasms
×
Rubidium-82
×
Clear all
NCT07099404
2025-08-22
PARAGON
Montreal Heart Institute
Not yet recruiting
20 enrolled